MEI Pharma, Inc.
COMBINATION THERAPIES
Last updated:
Abstract:
Provided herein are methods of treating and sensitizing cancer comprising administering a heterocyclic compound and a DNA hypomethylating agent.
Status:
Application
Type:
Utility
Filling date:
15 Dec 2020
Issue date:
8 Apr 2021